Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 46

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 46
---
31, 2025, our revenue fromTAKECAB/VOCINTI was JPY 130.8 billion.

•GATTEX/REVESTIVE(teduglutide [rDNA origin]), a treatment for patients with short bowel syndrome (SBS) who are dependent on parenteral support. GATTEX/REVESTIVE has been launched in the U. S., Europe and Japan with adult and pediatric indications. In the fiscal year ended March 31, 2025, our revenue fromGATTEX/REVESTIVE was JPY 146.3 billion.

In Rare Diseases, our principal products are:

• TAKHZYRO(lanadelumab-flyo), for the prevention of hereditary angioedema (HAE) attacks. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein, an enzyme which is chronically uncontrolled in people with HAE. TAKHZYRO was approved for patients 12 years and older in both the U. S. and Europe in 2018, in China in 2020 and in Japan in 2022 and we are working to expand into further geographic areas. In 2023, TAKHZYRO was also approved by the FDA and the European Commission in patients aged 2 years and older, and in February 2025, an additional 2 mL pre-filled pen option for the product was approved by theEuropean Medicines Agency(EMA) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema. In the fiscal year ended March 31, 2025, our revenue from TAKHZYRO was JPY 223.2 billion.

•LIVTENCITY(maribavir), a treatment for adults and pediatric patients (12 years and older and weighing at least 35 kg) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, foscarnet or cidofovir. LIVTENCITY launched in the U. S. in December 2021, and was approved in Europe in November 2022, and China in December 2023. LIVTENCITY continues to show strong launch performance driven by fast uptake, rapid geographic expansion and positive market access trends indicating high un